Torrent Pharmaceuticals Ltd
TORNTPHARMBSE 500420PharmaceuticalsMkt cap ₹1,81,123 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹4,921 Cr
YoY +54.8%QoQ +17.3%
Net profit · Q1 FY27
₹566 Cr
YoY +3.3%QoQ +55.5%
Net margin · Q1 FY27
11.5%
-5.7 pts vs Q1 FY26
Net profit · FY26
₹2,138 Cr
YoY +11.9%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 4,921 | 4,197 | 3,303 | 3,302 | 3,178 | +54.8% |
| Other income | -12.00 | -17.00 | -13.00 | -27.00 | -37.00 | — |
| Total income | 4,909 | 4,180 | 3,290 | 3,275 | 3,141 | +56.3% |
| Profit before tax | 733 | 529 | 814 | 791 | 738 | -0.7% |
| Tax | 167 | 165 | 179 | 200 | 190 | -12.1% |
| Net profit | 566 | 364 | 635 | 591 | 548 | +3.3% |
| Net margin | 11.5% | 8.7% | 19.2% | 17.9% | 17.2% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 13,980 | 11,516 | 10,728 | 9,620 | 8,508 | +21.4% |
| Other income | -94.00 | 23.00 | 58.00 | 45.00 | 197 | -508.7% |
| Total income | 13,886 | 11,539 | 10,786 | 9,665 | 8,705 | +20.3% |
| Profit before tax | 2,872 | 2,673 | 2,352 | 1,847 | 1,226 | +7.4% |
| Tax | 734 | 762 | 696 | 602 | 449 | -3.7% |
| Net profit | 2,138 | 1,911 | 1,656 | 1,245 | 777 | +11.9% |
| Net margin | 15.3% | 16.6% | 15.4% | 12.9% | 9.1% |
BIC's take
We haven't covered Torrent Pharmaceuticals Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 6:43 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.